Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
Oncotarget（2020）
摘要
FLT3FLT350FLT3FLT3FLT3
更多查看译文
关键词
AC886,FLT3 inhibitors,midostaurin resistance,quizartinib,relapsed/refractory AML
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要